Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Infection risk comparable between biologics, nonbiologics in children with psoriasis

04 Jun 2020

No substantial difference in infection risk is seen between biologics and nonbiologics among children with psoriasis, reveals a recent study. There is also no robust difference between systemic treatment and phototherapy.

“Independent of treatment, children with psoriasis had a higher risk of infection than those without psoriasis,” the authors said.

In this study, the authors estimated the 6-month risk of serious infections in children with psoriasis treated with biologics, systemic nonbiologics, and phototherapy. They used insurance claims data to identify children aged <18 years with psoriasis. The frequency of serious infections was compared in those initiating biologics, systemic nonbiologics, and phototherapy. Relative risks (RRs) were estimated before and after 1:1 propensity score matching.

A total of 57,323 children with psoriasis were identified. The 6-month infection risk was 4.2 per 1,000 patient-years in 722 biologic initiators, 5.1 in 988 systemic nonbiologic initiators, and 1.1 in 2,657 phototherapy initiators.

The RR was 0.67 (95 percent confidence interval [CI], 0.11–3.98) in biologics vs nonbiologics, 1.50 (95 percent, 0.25–8.95) in biologics vs phototherapy, and 5.00 (95 percent CI, 0.59–42.71) in nonbiologics vs phototherapy. Of note, the background risk of infection in children with psoriasis was 1 per 1,000, which was nearly double the risk compared with those without psoriasis (RR, 1.84, 95 percent CI, 1.15–1.97).

“Psoriasis is increasingly treated with systemic medications, yet their safety is not well characterized in children,” according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.